Univercells Technologies’ product offering includes the unique scale-X single-use structured fixed-bed bioreactor for the intensified production of viruses used in cell and gene therapy, viral vaccines and other therapeutics. The company’s automated NevoLine Upstream platform incorporates industry-standard filtration to provide integrated up- and mid-stream processing capabilities in a single unit driving productivity improvements, reduced operational footprints and greater consistency of results.
“The acquisition of Univercells Technologies represents an important next step in Donaldson’s life sciences strategy, as we continue to expand our product portfolio aimed at providing customers with a comprehensive, differentiated offering,” said Tod Carpenter, chairman, president and chief executive officer of Donaldson.
Mathias Garny, CEO of Univercells Technologies, said: “Our technology, complemented by Donaldson’s filtration excellence and existing life sciences capabilities is part of a larger vision to bring end-to-end solutions to market for advanced therapies.”
